NCT00175435View on ClinicalTrials.gov

Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Resiquimod gel

3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator

BIOLOGICAL

Resiquimod gel

3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.

BIOLOGICAL

Resiquimod gel

3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.

Trial Locations (1)

Unknown

Vancouver General Hospital Vaccine Education Centre, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER

NCT00175435 - Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator | Biotech Hunter | Biotech Hunter